Related Experiment Video
Updated: May 12, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind,
Ralf Gold1, Gavin Giovannoni, Krzysztof Selmaj
1St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. ralf.gold@ruhr-uni-bochum.de
Lancet (London, England)
|April 9, 2013
Summary
Daclizumab HYP significantly reduced relapse rates in relapsing-remitting multiple sclerosis patients over one year. This study suggests daclizumab HYP as a potential new treatment option for active MS.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Daclizumab is a monoclonal antibody targeting the IL-2 receptor alpha subunit (CD25).
- It modulates interleukin-2 signaling, crucial in immune responses.
- This study investigated daclizumab high-yield process (HYP) for relapsing-remitting multiple sclerosis (RRMS).
Purpose of the Study:
- To evaluate the efficacy of daclizumab HYP as monotherapy in RRMS patients.
- To assess its effect on disease activity over a 1-year treatment period.
- To determine if daclizumab HYP offers a new therapeutic option for RRMS.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 76 centers.
- Patients with RRMS received subcutaneous daclizumab HYP (150 mg or 300 mg) or placebo every 4 weeks for 52 weeks.
- The primary endpoint was the annualized relapse rate, analyzed by intention-to-treat.
Main Results:
- Daclizumab HYP (150 mg and 300 mg) significantly reduced the annualized relapse rate compared to placebo (54% and 50% reduction, respectively).
- A higher proportion of patients in the daclizumab HYP groups remained relapse-free (81% and 80%) versus placebo (64%).
- Serious adverse events were comparable across groups, with one fatality in the daclizumab HYP 150 mg group due to a complication of a psoas abscess.
Conclusions:
- Subcutaneous daclizumab HYP administered every 4 weeks demonstrated clinically significant effects on multiple sclerosis disease activity.
- The findings support daclizumab HYP as a potential additional treatment for relapsing-remitting multiple sclerosis.
- Further research may explore its long-term efficacy and safety profile.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.